Radiopharma AAA refiles for up to $75M IPO; Sterigenics does $15M expansion;

@FierceMedDev: Illumina expands in China with cancer Dx deal. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: U.K. patient group demands government override Roche's Kadcyla patents. Article | Follow @EmilyWFierce

> Radiopharmaceutical Dx player Advanced Accelerator Applications has refiled for an IPO--with plans to raise up to $75 million. It had previously filed for up to $100 million in November 2014. More

> Medical device sterilization company Sterigenics, which is backed by Warburg Pincus and GTCR, will spend $15 million so expand its capacity at an Arkansas facility. More

> PKA SoftTouch has started a $100K crowdfunding campaign on Indiegogo to back clinical testing for its insulin microneedle that offers a "virtually pain free" option. More

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

@DamianFierce: Today's the FDA decision deadline for Keytruda's lung cancer app. Can't wait to see the TV ad. | Follow @DamianFierce

> XenoPort hits reset after a psoriasis setback, cutting jobs and bailing on R&D. Report

> Regeneron inks a $325M deal, selling Asian rights to a pain treatment. Story

> Sanofi steps deeper into RNAi work, opts in on Alnylam hemophilia drug. Article

Pharma News

@FiercePharma: MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto. FiercePharmaMarketing story | Follow @CarlyHFierce

> Novartis targets Amgen's Enbrel with second biosimilar app. Story

> Ackman's fund takes a beating on Valeant pricing worries. Item

> FTC weighs in on Mylan case, saying generics tweaking may be anticompetitive. Article